Statistics
The Relmada Therapeutics stock price is currently $ 4.21 with a total market cap valuation of $ 449.08M (106.67M shares outstanding). The Relmada Therapeutics is trading on NASDAQ under the ticker sign RLMD. Relmada Therapeutics price is up
Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.
Company Profile
- Full Name: Relmada Therapeutics
- Sector: Healthcare
- Website: https://www.relmada.com
